Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684064 | 1.00 | CRBN (0.50) | CRBNDDB1ALDH1A1HPGDMEN1 | |
| SCHEMBL26683782 | 0.92 | CRBN (0.56) | CRBNDDB1ALDH1A1HPGDKDM4E | |
| SCHEMBL30450186 | 0.89 | CRBN (0.50) | CRBNDDB1ALDH1A1HPGDMEN1 | |
| SCHEMBL26684049 | 0.89 | CRBN (0.50) | CRBNDDB1ALDH1A1HPGDMEN1 | |
| SCHEMBL26684176 | 0.81 | CRBN (0.56) | CRBNDDB1ALDH1A1HPGDMEN1 | |
| SCHEMBL26684289 | 0.81 | CRBN (0.48) | CRBNDDB1ALDH1A1HPGDMEN1 | |
| SCHEMBL30450420 | 0.77 | CRBN (0.46) | CRBNDDB1ALDH1A1HPGDKDM4E | |
| SCHEMBL26683933 | 0.76 | CRBN (0.54) | CRBNDDB1ALDH1A1HPGDKDM4E | |
| SCHEMBL30449361 | 0.76 | CRBN (0.54) | CRBNDDB1ALDH1A1HPGDKDM4E | |
| SCHEMBL30688280 | 0.76 | CRBN (0.52) | CRBNDDB1ALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | CRBN 2312/4885DDB1 4162/4885ALDH1A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.